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Structured Abstract 
Objective Aortic stiffness is an important predictor of future morbidity and mortality. 
Diabetes is associated with increased aortic stiffness, but the importance of non-
diabetic glucometabolic status for accelerated aortic stiffening is unclear. We tested the 
hypothesis that adverse glucometabolic status is associated with accelerated aortic 
stiffening in non-diabetic individuals, independently of known risk factors for arterial 
stiffening. 
Research Design and Methods Glucometabolic status and other cardiovascular risk 
factors were assessed at baseline in 2008/09, and carotid femoral pulse wave velocity 
(cfPWV) at baseline and follow-up in 2012/13, in 4386 non-diabetic participants of the 
Whitehall II Study.  
Results The mean age of the cohort at cfPWV baseline was 60 years, and 74% were 
male. cfPWV increased from (mean±SE) 8.30±0.03 to 8.98±0.04 m/s over 4 years of 
follow-up. At baseline, cfPWV was associated with fasting and 2-hour postload glucose, 
HbA1c, and HOMA-insulin resistance (HOMA-IR). HbA1c and HOMA-IR were 
associated with progression of cfPWV after adjusting for physiological confounders and 
cardiovascular risk factors. A 1SD higher HbA1c and HOMA-IR were associated with 
greater increases in cfPWV (0.11m/s per 5 years, 95%CI 0.04, 0.18, P=0.003 and 
0.09m/s per 5 years, 0.01, 0.17, P=0.03, respectively). Additional adjustment for BMI 
weakened the association with HOMA-IR but not with HbA1c. 
Conclusions HbA1c is independently associated with accelerated progression of aortic 
stiffness in non-diabetic individuals. These findings suggest that long-term 
glucometabolic status, even in non-diabetic individuals, could be an important target for 
preventative strategies against vascular ageing.  
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Introduction  
 
Aortic stiffness provides important prognostic information on overall cardiovascular risk 
and mortality1. In the most recent meta-analysis, cfPWV, the current gold-standard 
measure of aortic stiffness, was an independent predictor of future cardiovascular 
events, improving risk classification beyond that provided by traditional risk factors2. 
This has added to the view that aortic stiffness is a measure of vascular health or 
vascular age3, 4 and has created considerable interest in aortic stiffness as a novel 
therapeutic target.  
 
The precise mechanisms underlying aortic stiffening remain poorly understood. The 
heterogeneity in the rate of stiffening suggests it is not an inevitable consequence of the 
ageing process5. A number of risk factors for accelerated aortic stiffening have been 
described, including elevated blood pressure, renal disease, systemic inflammation and 
adiposity 6-10. Diabetes has been linked with increased vascular stiffness in several 
case-control studies11-13, and HbA1c level is associated with an accelerated age-related 
increase in cfPWV in individuals with type 2 diabetes14. In non-diabetic individuals, 
cross-sectional studies suggest an association between aortic stiffness, glycaemia, and 
indices of insulin resistance11, 15, 16. However, a prospective analysis using Whitehall II 
data is equivocal, finding associations only in men 17. The evidence from longitudinal 
studies is also conflicting. Only one of seven previous longitudinal studies identified 
plasma glucose as an independent predictor of the rate of progression of cfPWV after 
adjusting for confounders, but only in women18. The remaining longitudinal studies 
report either no independent association 19-22, or did not examine glucose as a risk 
factor for stiffening23, 24. None of the studies provide any information concerning HbA1c 
and aortic stiffening.  
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We hypothesized that impaired glycaemic control is associated with accelerated aortic 
stiffening in non-diabetic individuals, and that this would be independent of known risk 
factors for arterial stiffening. Our aim was to test this hypothesis in the Whitehall II 
longitudinal study. This cohort study provides data on progression of cfPWV over a 4 
year interval, together with repeated assessments of glycaemia, insulin resistance, 
anthropometric parameters and cardiovascular risk factors. We excluded individuals 
with clinical or biochemical evidence of diabetes to reduce the confounding effects of 
treatment and diabetic complications such as renal disease which may themselves alter 
stiffness.  
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Research Design and Methods 
Participants 
All participants were drawn from the Whitehall II cohort, a longitudinal observational 
study of 10,308 civil servants recruited between 1985-8 when aged 35-55 years old25. 
Participants have been followed-up every 4-5 years, with detailed clinical examinations 
and self-administered questionnaires in 1991-94, 1997-99, 2003-04, 2008-09 and 2012-
13. For each examination phase, Research Ethics Committee approval was obtained, 
and participants gave written informed consent.  
 
A total of 4347 out of 6225 participants seen at the screening clinic in 2008-09, and 
4485 out of 5660 seen at 2012-13, underwent cfPWV assessment. The present analysis 
was based on non-diabetic participants. Diabetes was defined by self-report/doctor 
diagnosed, the use of anti-diabetic medication, fasting glucose ≥7.0, a 2hr glucose 
≥11.1 mmol/L during an oral glucose tolerance test or HbA1c ≥ 6.5% (48mmol/mol). 617 
participants met these criteria at baseline and 582 at follow-up, and were therefore 
excluded from all analyses, together with a further 95 participants at baseline and 301 at 
follow-up who had missing data on covariates. This left 4386 non-diabetic participants 
who underwent cfPWV assessment during the 2008-9 (n=3685) and/or 2012-3 (n=3602) 
examinations who make up the analytic sample. 2901 participants underwent cfPWV 
assessments at both time points. The same measurement protocol was used at each 
examination. 
 
Measurements 
Pulse wave velocity 
Aortic stiffness was assessed by cfPWV, the current non-invasive gold-standard26. 
Higher values of cfPWV indicate a faster speed of wave travel between the arterial sites 
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and, hence, a stiffer aorta., Measurements were made after 15 minutes supine rest, in 
duplicate, using the SphygmoCor system (AtCor Medical, Sydney), as previously 
described27. Briefly, brachial blood pressure was measured and then cfPWV assessed 
between the carotid and femoral sites. Path length was determined with a tape 
measure, by subtracting carotid-sternal notch distance from femoral-sternal notch 
distance. If the difference between repeated measurements was >0.5m/s, a third 
measurement was taken, with the average of measurements used in the analysis. Heart 
rate was derived from the SphygmoCor software and blood pressure was measured 
using a validated oscillometric device immediately prior to cfPWV. Mean arterial 
pressure (MAP) was calculated as diastolic pressure plus one third of the pulse 
pressure. 
 
Vascular disease, diabetes and anti-hypertensive medication 
Prevalent vascular disease status (myocardial infarction and/or stroke) at the 2008-09 
assessment was determined using self-report doctor diagnosis and hospitalization with 
verification from medical records where available. Prevalent diabetes was determined 
by oral glucose tolerance test, self-report doctor diagnosis and/or medication28. 
 
Anthropometry and other covariates 
Anthropometric measures and cardiovascular risk factors were measured in 2003-04 
and 2008-09 to provide mean exposure in the 5 years before baseline cfPWV 
assessment in 2008-09. Weight, height, and waist and hip circumferences were 
measured using standard protocols29. Serum, fluoride plasma and EDTA blood was 
collected after overnight fast or ≥5 hours after a fat-free breakfast for participants 
presenting in the afternoon. Serum total cholesterol, high density lipoprotein cholesterol 
(HDL), triglycerides and plasma glucose, were measured. 
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Glucometabolic measures 
Samples were handled according to standard protocols. Venous blood samples were 
taken in fasted individuals (≥8 h of fasting or ≥5 h for afternoon visits), before a standard 
2-h oral glucose tolerance test was administered in all participants29. Glucose samples 
were drawn into fluoride monovette tubes and insulin samples into native tubes which 
were centrifuged on site within 1 h. Plasma or serum was immediately moved into 
microtubes and stored at –70oC. Blood glucose was measured using the glucose 
oxidase method30 on YSI model 2300 STAT PLUS analyser (2003-04, and 2007-09), 
mean CV 1·4–3·1%) (YSI Corporation, Yellow Springs, OH, USA), and serum insulin 
with a DAKO insulin ELISA kit (DakoCytomation Ltd, Ely, UK)31 (2003-04, mean CV 
4·2–9·3%, 2007-09). HOMA insulin sensitivity and HOMA β-cell function were 
calculated on the basis of model-derived estimates (rather than linear approximations) 
with the HOMA2 calculator version 2.232. Haemoglobin A1c (HbA1c) was measured in 
whole blood, drawn into EDTA monovette tubes, using the validated33 Tosoh G8 high 
performance liquid chromatography platform (Tosoh Bioscience, Belgium). 
 
The exposures and covariates used in the analyses were the mean values of risk 
factors assessed in 2003-4 and 2008-9 since, compared to a single measurement at 
2008-09, these provide more reliable estimates of exposure in the 5 years prior to the 
first cfPWV measurement. 
 
Statistical analysis 
Distributions of glucometabolic indices among people without diabetes were categorised 
in sex-specific quintiles and also expressed in standardised units. Linear mixed models 
were used to estimate the relation of glucometabolic indices with cfPWV in 2008-09 and 
change in cfPWV between 2008-09 and 2012-13. These models used all available 
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cfPWV data, including cases where only one cfPWV measurement was available, which 
reduced selection bias and allowed better estimates of the associations of potential 
confounding factors. The models also accounted for correlation between repeated 
measures within individuals. We fitted the models with a random intercept and slope to 
account for individual differences in cfPWV at baseline and rate of change over follow-
up. From these models, the effect of each glucometabolic index on cfPWV at baseline 
(2008-2009) is estimated by the coefficient for the main effect of the glucometabolic 
index and the effect on progression of cfPWV between 2008-09 and 2012-13 is 
estimated by the interaction of the main effect with time. The longitudinal effects of the 
glucometabolic indices have been expressed as 5-year changes in cfPWV to allow 
direct comparisons with previous studies18, 20, 24. All estimates were initially adjusted for 
age, sex, ethnic group, heart rate and MAP at the time of cfPWV measurement. 
Baseline cfPWV and progression of cfPWV per 5 years were estimated from these 
models by quintile of each glucometabolic index distribution and per 1SD increment in 
each index. This allowed us to examine associations with cfPWV across the distribution 
of each glucometabolic index and whether the coefficients increased linearly across 
quintiles. Tests of heterogeneity were conducted using likelihood ratio tests that 
compared the fit of the models with and without the quintiles of each glucometabolic 
measure. Two further models cumulatively adjusted for: (i) systolic blood pressure, 
antihypertensive medication, lipid lowering medication, smoking status, prevalent MI or 
stroke and mean triglyceride and HDL-cholesterol between 2003-04 and 2008-09 and 
(ii) mean BMI between 2003-04 and 2008-09 and estimated glomerular filtration rate 
(eGFR) in 2008-09. Sensitivity analysis was conducted to compare characteristics of 
participants with and without measurements of cfPWV, in order to exclude the possibility 
of selection bias. Further sensitivity analyses used the glucometabolic measures from 
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baseline (2008-09) or pre-baseline (2003-04), rather than averaging the glycaemic 
measures across the two phases.  
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Results  
The mean age of the cohort at the time of the baseline cfPWV assessment was 60 
years, 74% were male, and predominantly of white ethnic origin. Fewer than 5% had 
chronic disease, and ~30% were taking antihypertensive medication. A comparison of 
participants with and without cfPWV assessments across the entire cohort revealed that 
those individuals who did not have cfPWV measured were more likely to be female and 
have generally poorer health, in terms of chronic disease and taking anti-hypertensive 
or lipid-lowering medication (supplementary Table S1). Detailed participant 
characteristics for the two-cfPWV examination time points are provided in Table 1. 
Measures of exposure that were averaged across the pre-baseline (2003-4) and 
baseline (2008-9) cfPWV visits are presented separately for each examination phase in 
supplementary Table S2.  
 
There was no evidence that the associations of the glucometabolic indices with baseline 
cfPWV and progression of cfPWV differed between men and women (Table S3). Cross-
sectional associations between cfPWV and glucometabolic indices are shown by 
quintile in Table 2; adjusted for age, gender, ethnicity, MAP and heart rate. There were 
significant positive associations with fasting glucose, 2hr glucose, HbA1c and HOMA-
IR. cfPWV increased by between 0.19 and 0.40 m/s when moving from the lowest to 
highest quintile of each determinant. Additional adjustment for other potential 
confounders, including drug therapy and cardiovascular risk factors, only modestly 
attenuated these associations (supplementary Table S4). When glucometabolic 
measures were treated as continuous variables, glucose and HOMA-IR were strongly, 
and HbA1c weakly, associated with baseline cfPWV (Table 3). These associations were 
weakened with additional adjustment for potential confounders.  
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After adjustment for age, sex, ethnicity, MAP and heart rate, only HbA1c and HOMA-IR 
were significantly associated with progression of cfPWV. There was a 0.39 m/s greater 
increase in cfPWV over 5 years in individuals in the top quintile of either parameter, 
compared with those in the lowest quintile (Table 2 and Figure 1). Adjustment for 
treatment and other risk factors (supplementary Table S5) did not significantly attenuate 
these associations. However, after the addition of BMI to the models, there was no 
longer an association with HOMA-IR. Analyses using the continuous variables revealed 
similar findings – a 1SD higher HbA1c or HOMA-IR at baseline was associated with a 
~0.12m/s greater increase in cfPWV over 5 years (Table 3). In the fully adjusted model, 
only HbA1c was associated with progression in cfPWV. 
 
Repeating these analyses using glucometabolic measures from baseline (2008-09) or 
pre-baseline (2003-04), rather than averaging across the two phases did not 
meaningfully alter the results (supplementary Tables S6 and S7, respectively). 
Similarly, excluding the 1.1% of individuals who developed diabetes during follow-up 
had no influence on the results (data not shown). In order to exclude the possibility of a 
selection bias influencing our results, since measurement of cfPWV was not undertaken 
in all participants, a separate analysis using the entire cohort, explored the relationship 
between HbA1c and blood pressure, which is closely related to cfPWV. At baseline and 
follow-up, HbA1c was ~3% higher in hypertensives than non-hypertensives, in those 
with and without cfPWV assessment, after adjusting for confounding factors 
(supplementary Table S8). This supports our observed association between HbA1c and 
cfPWV and argues against the possibility that selection bias might be influencing our 
findings.  
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Conclusions 
Our main findings are that, glucose, HbA1c and insulin resistance are all cross-
sectionally associated with aortic stiffness, and that in longitudinal analysis, HbA1c and 
HOMA-IR are associated with the progression of aortic stiffness over a 4-year period. 
These associations were independent of other cardiovascular risk factors. The 
association between HbA1c and aortic stiffening was also independent of BMI. These 
observations suggest that factors underlying glucometabolic status may affect aortic 
stiffening even within the normoglycaemic range, which may have important 
implications for developing anti-stiffening strategies and exploiting novel therapeutic 
targets.  
 
Aortic stiffness, and cfPWV in particular, is an important risk factor for future 
cardiovascular disease, independently of other cardiovascular risk factors2. However, 
the biological processes underlying aortic stiffening are incompletely understood. Cross 
sectional analyses have provided inconsistent results6, and are limited in their ability to 
attribute causality. Existing longitudinal data highlight the importance of age and blood 
pressure, but the importance of other potential risk factors, including indices of glucose 
homeostasis, is unclear, due to lack of replication studies, variable lengths of follow-up, 
poor availability of data on individual risk factors, and variation in adjustment for 
confounders. Whitehall II is a large cohort with prospective data on cfPWV and other 
risk factors including a variety of glucometabolic indices, making it well suited to 
examine the relationship between glycaemia and aortic stiffening in non-diabetic 
individuals.  
 
As expected, we found significant cross-sectional relationships between indices of 
glucose homeostasis and insulin resistance with cfPWV. Importantly, this remained after 
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adjustment for physiological confounders of stiffness such as MAP and heart rate34. 
Similar results have been reported previously using a variety of study designs, indices 
of stiffness, and varying levels of adjustment for physiological confounders 11, 15, 16, 35, 36. 
In the present study, adjustment for other potential risk factors for arterial stiffening or 
cardiovascular disease only modestly reduced the strength of association with glucose 
measures, but the associations with HOMA-IR and HbA1c were more markedly 
attenuated, with an approximate halving of the beta values. This contrasts with cross-
sectional findings from a cohort of 263 African-Americans16, in whom HbA1c, but not 
fasting, or 2–hr glucose levels remained independently associated with cfPWV. This 
disparity possibly reflects ethnic differences in the association between HbA1c and 
arterial stiffness, or may reflect a lack of appropriate statistical power in the African-
American study. In addition, we a priori excluded diabetic individuals, which may have 
removed any association with HbA1c in our data. Alternatively, residual confounding 
may explain our observed associations with plasma glucose. 
 
In contrast to the cross-sectional observations, fasting and 2-hr glucose were not 
associated with progression of aortic stiffening in the current study, which is consistent 
with previous observations19-22. However, HbA1c and HOMA-IR were associated with 
accelerated progression of cfPWV, independently of potential confounders. Previously, 
one small study reported no association between cfPWV progression and HOMA19, but 
HbA1c has been associated with progressive carotid artery stiffening in the ARIC 
Study37, although unfortunately, cfPWV was not assessed. In the current study, cfPWV 
increased by ~0.7m/s, which is consistent with previous longitudinal studies which have 
reported increases of between 0.2 and 0.6 m/s per 5 years, in participants aged ~60 
years18, 20, 24. Moreover, modest differences of 0.07% in HbA1c or 0.67 units in HOMA-
IR were associated with a ~0.1m/s greater increase in cfPWV over 5 years, equating to 
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~12-14% of the overall change in stiffness. While the rate of stiffening is strongly 
dependent on age, our data suggest that even in non-diabetic individuals, modest 
differences in glucometabolic status have a meaningful impact on arterial stiffening, 
consistent with our hypothesis of accelerated vascular ageing. 
 
There is a strong mechanistic relationship between measures of adiposity, insulin 
resistance and glycaemia. We and others have previously reported that measures of 
adiposity including BMI are associated with accelerated aortic stiffening, independent 
from other risk factors10, 18, 20, 22. Therefore, we additionally adjusted for BMI. After this, 
HbA1c, but not HOMA-IR, remained predictive of aortic stiffening. These findings 
suggest that adiposity and insulin resistance share common pathway(s) leading to aortic 
stiffening, but that these pathways may be independent of glycaemia, although this 
hypothesis requires further examination. A number of mechanisms may be responsible, 
including visceral and perivascular fat accumulation, and the vascular effects of insulin. 
Indeed, fasting insulin concentrations are positively associated with cfPWV in the 
general population 38. In addition, abdominal and vascular adiposity alter adipokine 
levels, increase circulating pro-inflammatory stimuli, and may directly inflame the 
vasculature 39-41. Low adiponectin levels have previously been associated with obesity 
and increased cfPWV progression19, and in the Whitehall II cohort we have previously 
shown that a panel of inflammatory markers are associated with increased cfPWV 16 
years later17. 
 
Systemic inflammation is also associated with cfPWV7, 42. Interestingly, the peroxisome 
proliferator–activated receptor γ (PPAR-γ) agonist, pioglitazone, improves inflammation 
and glycaemic control in obese, diabetic patients43. Pioglitazone was also effective in 
preventing strokes44 and in reducing the progression to diabetes and major 
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cardiovascular events45 in a high-risk non-diabetic population. As such, PPAR-γ 
agonists may represent one potential therapeutic strategy to retard aortic stiffening in 
non-diabetic individuals. In addition, formation of advanced glycation end-products 
(AGEs), which accumulate in tissues over time and with increased plasma glucose 
levels46, correlate with aortic stiffness in non-diabetic individuals47, 48. Experimental 
cross-link breakers reduce cfPWV and pulse pressure in animals49 and humans50 and 
our longitudinal finding for HbA1c suggests that AGEs may represent another novel 
anti-stiffening target, even in non-diabetic individuals. However, both of these 
hypotheses need to be tested in well-designed intervention studies. 
 
The present study has a number of limitations. We were restricted to 4 year follow-up 
data, and cannot exclude the possibility that differences in relative strength of the 
glucometabolic risk factor effects may be observed with longer follow-up, or indeed in 
younger adults. However, our data are consistent with observations made in other 
cohorts with similar lengths of follow up. Moreover, we used the gold-standard method 
of cfPWV to assess aortic stiffness and an identical protocol at both examinations. 
However, use of a 5 hour fast for afternoon examinations may have meant that those 
participants were not truly fasted. We are unable to comment on the impact of diabetes 
per se because we a priori excluded diabetic individuals. This allowed us to minimize 
potential confounding influences, such as therapy. However, we were able to 
demonstrate meaningful differences in progression of aortic stiffness, even within what 
is considered a normal range of HbA1c. Given that glucometabolic indices determine 
the development of diabetes up to 15 years in advance51 and cfPWV predicts future 
cardiovascular risk2, we believe that our observations are clinically important and 
suggest that further mechanistic and intervention studies of arterial stiffening should 
examine factors related to longer-term glucometabolic status. These could involve 
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lifestyle approaches and/or trials of glucose-lowering therapies in non-diabetic 
individuals, which could ultimately influence public health strategies. 
 
In summary, in non-diabetic individuals, a higher HbA1c and HOMA-IR is associated 
with increased aortic stiffening. This was independent of potential confounders, or other 
cardiovascular risk factors, and, in the case of HbA1c, also independent of BMI. In 
contrast, point-estimates of glucose, either fasting or 2-hours post a standard glucose 
tolerance tests, were not associated with progression of aortic stiffness. Our data 
suggest that higher average glucose levels may be causally related to accelerated 
vascular ageing through long-term mechanisms rather than short-term dynamic 
changes in the arterial wall. As such, improving glucometabolic status may represent a 
strategy to improve vascular health.  
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Figure Legends 
 
Figure 1. The association between HbA1c and change in cfPWV  
 
Plotted points show the cfPWV change per 5 years for each quintile of HbA1c, plotted at 
the median of each quintile. Solid line shows linear association, dashed lines show the 
95% confidence interval. Values shown are adjusted to non-diabetic white men at age 
65 with a mean arterial pressure of 90mmHg. Test for quadratic (nonlinear) effect gave 
a P-value=0.48. 
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Table 1. Characteristics of participants who were non-diabetic at baseline 
Characteristic 
Baseline (2008-2009) 
(N=3685) 
 
Follow-up (2012-2013) 
(N=3602) 
 Mean (SD)    %   Mean (SD)    %  
      
Age, y 60.1 (5.7)   65.0 (5.6)  
      
Female  25.6    25.7  
      
Ethnic group:  White  94.0    94.6  
                          South Asian    3.2      2.8  
                          Black    2.1      1.9  
                          Other    0.7      0.7  
      
Diabetes    0.0      1.1  
      
MI or Stroke     4.9      4.5 
      
Anti-hypertensive medication   29.1    36.0 
      
Lipid lowering medication   26.7    36.6 
      
Ex-smoker  45.2   48.8 
Current smoker     5.2     3.1 
      
Body mass index, kg/m
2
 26.0
 
 (3.7)   26.0 (3.9)  
      
Systolic blood pressure, mmHg 124.2
 
 (15.3)   126.7 (15.9)  
      
Diastolic blood pressure, mmHg 70.8
 
 (10.0)   70.8 (9.8)  
      
Triglyceride,
 
 mmol/L 1.16
 
 (0.65)   1.13 (0.57)  
      
HDL cholesterol, mmol/L 1.63
 
 (0.45)   1.68 (0.47)  
      
LDL cholesterol,
 
 mmol/L 3.14
 
 (0.94)   2.98 (0.94)  
      
Fasting glucose,
 †
 mmol/L 5.05* (0.10)   5.16* (0.10)  
      
2-hour glucose,
 †
 mmol/L 6.23* (0.26)   Not done
 
 
      
HbA1c,
 †
 % 5.58*
 
 (0.07)   5.64* (0.06)  
      
HbA1c, 
† mmol/mol 37.4* (0.07)   38.4* (0.06)  
HOMA-IR,
 †
 1.39*
 
 (0.67)   1.68* (0.66)  
      
Heart rate, bpm 65.8 (11.3)   68.1 (11.6)  
      
cfPWV, m/s 8.30 (1.93)   8.98 (2.39)  
      
Mean arterial pressure, mmHg 89.4 (10.5)   93.8 (10.9)  
      
Characteristics of the participants included in the present analyses at the baseline (2008-
2009) and follow-up (2012-2013) visits. For glucometabolic indices (†) the baseline values 
represent the average of values at the 2003-04 and 2008-09 assessments. The mean for 
all 4386 participants included in the analyses is shown in supplementary Table S2, 
together with the separate means for 2003-04 and 2008-09. *Geometric mean and SD of 
logged values.
 
Table 2. The association of glucometabolic indices at baseline with cfPWV measured at baseline and progression of cfPWV over 
the follow-up period  
Glucometabolic measure
a
  
  
cfPWV at baseline  
Change in cfPWV  
(per 5 years) 
 
Median 
Person 
Obs 
 
Mean
b
 
Difference
c
  
(95% CI) 
P-value  Mean
b
 
Difference
c
  
(95% CI) 
P-value 
           
Fasting glucose, mmol/L  (7287)         
       Q1 - lowest quintile   4.65 1512  8.30 Ref -  0.58 Ref - 
       Q2 4.93 1251  8.33 0.04 (-0.13, 0.21) 0.64  0.60 0.02 (-0.21, 0.25) 0.89 
       Q3  5.10 1521  8.39 0.11 (-0.05, 0.27) 0.18  0.59 0.01 (-0.20, 0.23) 0.91 
       Q4  5.35 1603  8.50 0.22 (0.06, 0.37) 0.007  0.57 0.00 (-0.21, 0.22) 0.99 
       Q5 - highest quintile   5.70 1400  8.52 0.27 (0.11, 0.43) 0.001  0.59 0.02 (-0.20, 0.24) 0.87 
           
Heterogeneity (P-value)     0.005    1.0  
Per 1SD higher fasting glucose    0.08 (0.03, 0.13) 0.004   0.01 (-0.07, 0.08) 0.89 
           
2-hour glucose, mmol/L  (7055)         
       Q1 - lowest quintile   4.65 1468  8.15 Ref -  0.53 Ref - 
       Q2 5.55 1488  8.26 0.11 (-0.05, 0.27) 0.18  0.53 0.00 (-0.22, 0.21) 0.97 
       Q3  6.20 1379  8.32 0.17 (0.00, 0.33) 0.05  0.52 -0.01 (-0.24, 0.21) 0.90 
       Q4  6.90 1409  8.25 0.10 (-0.06, 0.26) 0.22  0.56 0.03 (-0.19, 0.26) 0.76 
       Q5 - highest quintile   8.25 1311  8.46 0.32 (0.15, 0.48) <0.001  0.73 0.20 (-0.03, 0.43) 0.09 
           
Heterogeneity (P-value)     0.006    0.36  
Per 1SD higher 2-hour glucose    0.11 (0.06, 0.16) <0.001   0.07 (-0.01, 0.14) 0.07 
           
HbA1c, %  (7283)         
       Q1 - lowest quintile   5.0 1472  8.35 Ref -  0.44 Ref - 
       Q2 5.2 1197  8.26 -0.08 (-0.25, 0.09) 0.33  0.58 0.14 (-0.09, 0.37) 0.24 
       Q3  5.4 1930  8.39 0.04 (-0.11, 0.19) 0.60  0.49 0.05 (-0.15, 0.26) 0.62 
       Q4  5.6 1418  8.56 0.21 (0.04, 0.37) 0.01  0.55 0.11 (-0.11, 0.33) 0.34 
       Q5 - highest quintile   5.8 1266  8.54 0.19 (0.02, 0.36) 0.03  0.83 0.39 (0.15, 0.62) 0.001 
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Heterogeneity (P-value)     0.003    0.01  
Per 1SD higher HbA1c    0.05 (0.00, 0.11) 0.05   0.12 (0.04, 0.19) 0.002 
           
HOMA-IR  (7189)         
       Q1 - lowest quintile   0.73 1583  8.21 Ref -  0.41 Ref - 
       Q2 1.12 1480  8.24 0.03 (-0.12, 0.19) 0.67  0.47 0.06 (-0.16, 0.27) 0.61 
       Q3  1.53 1474  8.46 0.26 (0.10, 0.41) 0.002  0.60 0.19 (-0.03, 0.40) 0.09 
       Q4  2.12 1415  8.55 0.35 (0.19, 0.51) <0.001  0.62 0.20 (-0.02, 0.42) 0.07 
       Q5 - highest quintile   3.52 1237  8.61 0.40 (0.23, 0.57) <0.001  0.80 0.39 (0.15, 0.62) 0.001 
           
Heterogeneity (P-value)     <0.001    0.01  
Per 1SD higher HOMA-IR    0.15 (0.10, 0.21) <0.001   0.11 (0.04, 0.19) 0.004 
           
a Values are the averages of measurements made at 2003-04 and 2008-09.  
b Means are adjusted for age, sex, ethnic group, heart rate and mean arterial pressure at the time of the cfPWV measurement and are 
shown adjusted to non-diabetic white men at age 65 with a mean arterial pressure of 90mmHg.  
c Differences are adjusted for age, sex, ethnic group and mean arterial pressure at the time of the cfPWV measurement. 
 Table 3. The associations of glucometabolic indices with cfPWV and progression 
of cfPWV after adjustment for confounding factors and other cardiovascular risk 
factors 
Glucometabolic 
measure
a
 
Model 
adjustments 
cfPWV at baseline 
 
 
Change in cfPWV 
(per 5 years) 
Difference
b
  
(95% CI) 
P-value  
Increase
b
  
(95% CI) 
P-value 
       
Fasting glucose Model 1
c
 0.08 (0.03, 0.13) 0.004  0.01 (-0.07, 0.08) 0.89 
 Model 2
d
 0.05 (-0.01, 0.10) 0.08  -0.01 (-0.08, 0.07) 0.87 
 Model 3
e
 0.05 (-0.01, 0.10) 0.09  -0.03 (-0.10, 0.04) 0.44 
       
2-hour glucose Model 1
c
 0.11 (0.06, 0.16) <0.001  0.07 (-0.01, 0.14) 0.07 
 Model 2
d
 0.06 (0.01, 0.12) 0.03  0.06 (-0.02, 0.13) 0.12 
 Model 3
e
 0.06 (0.00, 0.11) 0.04  0.04 (-0.03, 0.12) 0.24 
       
HbA1c Model 1
c
 0.05 (0.00, 0.11) 0.05  0.12 (0.04, 0.19) 0.002 
 Model 2
d
 0.04 (-0.02, 0.09) 0.19  0.11 (0.04, 0.18) 0.003 
 Model 3
e
 0.03 (-0.02, 0.09) 0.22  0.10 (0.03, 0.17) 0.008 
       
HOMA-IR Model 1
c
 0.15 (0.10, 0.21) <0.001  0.11 (0.04, 0.19) 0.004 
 Model 2
d
 0.07 (0.01, 0.13) 0.03  0.09 (0.01, 0.17) 0.03 
 Model 3
e
 0.07 (0.00, 0.13) 0.05  0.02 (-0.07, 0.11) 0.63 
       
a Values are the averages of measurements made at 2003-04 and 2008-09.  
b Differences and increases in pulse wave velocity are per 1SD higher value for each 
glucometabolic measure 
c Model 1 is adjusted for age, sex, ethnic group, heart rate and mean arterial pressure at 
the time of the cfPWV measurement 
d Model 2 is adjusted as for Model 1 + systolic blood pressure, antihypertensive 
medication, lipid lowering medication, prevalent MI or stroke, smoking status and mean 
triglyceride and HDL-cholesterol between 2003-04 and 2008-09 
e Model 3 is adjusted as for Model 2 + mean BMI between 2003-04 and 2008-09 
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Figure 1 
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